Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Good News On Actemra In Severe COVID-19 – But Will Roche File For Approval?

Another Significant RECOVERY Result

Executive Summary

The RECOVERY trial has found Actemra to help cut deaths and speed recovery – and UK doctors are not waiting for Roche to complete its own studies.

You may also be interested in...



Coronavirus Notebook: UK To Speed Up Trials Of New Drugs, Expands Use Of Tocilizumab

AstraZeneca and BioNTech are both boosting production of their vaccines in Europe, and the first batches of Comirnaty have arrived in Australia and New Zealand.

Don’t Write Actemra Off Yet: Roche Drug Found To Be Lifesaving In COVID-19

After failing in five earlier trials, Actemra shows significant life-saving benefits for patients with severe COVID-19.

COVID-19 Vaccine Gives Moderna $18bn Launchpad Into HIV Vaccine, Cancer Therapies

A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.

Topics

Related Companies

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel